Tirzepatide vs. liposuction: what the weight loss data actually shows

What did @aprendendo.tirzep actually say?

Honestly? It's hard to tell. The transcript from this video is largely incoherent, with lines like "I'm like this guy of fish" and "he's going to be a little bit pregnant" that don't map onto any recognizable medical claim. The hashtags, tirzec, lipoless, and tirzepatida, suggest the creator is in the tirzepatide space, but the spoken content doesn't deliver a coherent message about the drug.

This looks like an auto-generated or badly corrupted transcription of a video that may have been recorded in Portuguese, given the handle @aprendendo.tirzep and the hashtag "tirzepatida," which is the Portuguese-language spelling of tirzepatide. What was actually said cannot be fairly assessed from this transcript. That matters, because fact-checking a word salad isn't fact-checking. It's guesswork.

Does the science back this up?

There are no verifiable scientific claims to evaluate in the transcript. But since the hashtags clearly flag tirzepatide as the subject, here is what the actual evidence says, so you have a baseline for comparison.

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for obesity). The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that adults with obesity taking tirzepatide 15 mg lost an average of 20.9% of body weight over 72 weeks compared to 3.1% with placebo. That is a clinically significant result and one of the largest weight-loss signals ever seen in a pharmacological trial. The SURPASS trial series (Frías et al., 2021, New England Journal of Medicine) demonstrated robust A1C reductions in type 2 diabetes patients. These are real findings, published in peer-reviewed journals. Any content creator working in this space should be grounding their claims in this literature.

What did they get wrong (or right)?

This is where it gets awkward. There is nothing to specifically credit or correct because no intelligible claim was made. What we can say is that the hashtag "lipoless" is worth scrutinizing. It is a term circulating in Brazilian social media communities suggesting that tirzepatide can replace liposuction or produce liposuction-equivalent body composition changes. That framing is misleading.

Tirzepatide produces weight loss primarily through caloric restriction driven by appetite suppression and improved metabolic signaling. It does not selectively remove fat deposits the way liposuction does. A 2023 sub-analysis from the SURMOUNT program showed meaningful reductions in waist circumference and visceral fat, but that is not the same mechanism or the same result as a surgical procedure. Equating the two overpromises the drug and potentially steers people away from procedures that may be medically appropriate for them. If this video is implying "lipoless" as a product or protocol, that claim does not hold up to scrutiny.

What should you actually know?

Tirzepatide is a legitimate, FDA-approved medication with strong clinical trial data behind it. It is not a miracle, and it is not a surgical replacement. The weight loss seen in trials occurs in the context of structured clinical care, dose titration over months, and ongoing monitoring for side effects including nausea, pancreatitis risk, and thyroid considerations.

If you are watching TikTok content about tirzepatide, including this video, here is what to look for. Does the creator cite actual studies? Do they distinguish between compounded tirzepatide and brand-name Zepbound or Mounjaro? Do they acknowledge side effects? Those are the floor for responsible health content. A transcript full of non-sequiturs tied to weight-loss hashtags does not meet that floor. Seek information from licensed providers, not from videos where the most coherent sentence is "we are going to win."